Share

Huapont Life Sciences Co.,Ltd. Stocks

CN¥ 4.95Last Updated 27.04.2026

Issuer Rating

6/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.51B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 4.95
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Huapont Life Sciences Co., Ltd. engages in the pharmaceutical and agrochemical businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and intermediates. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and ophthalmology, as well as health management products. In addition, the company provides pesticide technical, intermediate and preparation products, and GLP registration technical services. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co., Ltd. in September 2015. Huapont Life Sciences Co., Ltd. was founded in 2001 and is based in Chongqing, China. Huapont Life Sciences Co., Ltd. was formerly a subsidiary of Huipont Tourism Co. Ltd.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is neutral on EV/EBITDA, underpr

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks